Sentinel lymph node dissection (SLND) has been shown to be a reasonable treatment option for early-stage breast cancer. Until recently, SLND was limited to clinical trials. Because this technique is now offered outside of trials, its prevalence is unknown.
UCLA School of Medicine, Robert Wood Johnson VA Clinical Scholars Program, 911 Broxton Avenue, 3rd Floor, Los Angeles, California 90024, USA. mmaggard@mednet.ucla.edu
